EFFECT OF SITAGLIPTIN ON BLOOD PRESSURE IN PRE-HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES
Objective: To determine the effects of Sitagliptin on pre-hypertensive type-2 diabetes mellitus patients.
Methods: This Quasi-Experimental study was conducted at Medical inpatient and outpatient department and Diabetic Clinic of Mayo Hospital, Lahore, from February 2019 till January 2020. A total of 146 patients were included in study. Blood pressure (BP) was recorded at baseline and then at 3, 6 and 12 months of treatment. Patients were called for follow up at 3 and 6 months, their BP was checked and haemoglobin A1c (HbA1c) was also sent to check for glycemic control. At 12 months, final follow up was called. BP and HbA1c of every patient were checked and recorded. The blood pressure values at baseline, 3 months, 6months and 12 months were comparatively analyzed by using a paired t-test and p-value of 0.05 was considered significant.
Results: Total 146 patients of type-2 diabetes with HbA1c ≤ 9 % not taking sitagliptin previously were selected for this study. Mean age of the patients was 57.5±10.7 years. Total 93(63.7%) were males and 53(36.3%) females. There was statistical difference of HbA1c, systolic and diastolic blood pressure values (p<0.05) after 3 months, 6 months and 12months of sitagliptin therapy as compared to baseline.
Conclusions: Sitagliptin therapy significantly decreases blood pressure and levels of HbA1c in type 2 diabetic-hypertensive patients.